Dr. Wanrudee Isaranuwatchai is a Secretary General and Senior Researcher of the Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand. She is also an Affiliated Scientist at St. Michael’s Hospital, and an Associate Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, in Canada.H

Digital health technologies (e.g., wearables, electronic health records, and artificial intelligence tools) are increasingly recognized for their potential to enhance care quality, efficiency, and reach of healthcare services while potentially reducing costs [1]. Landscape reviews have shown increasing investments by governments and other stakehold

68401067EU030L0Carbon resilient,Climate resilient,Green HTA,Health sector

68136067MU028L0medical innovation,health technology assessment,health economic evaluation,target product profiles,research and development

68305067HI027L0Research capacity building,health technology assessment,policy decision making,multidisciplinary research network,international collaboration

It is vital to have evidence-informed clinical practice guidelines or clinical indications to guide the usage of high-cost drugs in the benefits package under the Indonesian universal health coverage (JKN), managed by BPJS Kesehatan. A transparent and legit mechanism is required to support and mo

Colorectal cancer is the third most common cancer in Indonesia with approximately 28,000 patients diagnosed each year. Without population-based screening, patients are often treated when they reach the advanced stage. Bevacizumab, a newly available high-cost treatment for metastatic colorectal ca

Chayapat Rachatan is currently a Project Associate at HITAP. She supports the HTA and health system research. Her research studies focus on COVID-19 policy research and decision support, effectiveness evaluation of COVID-19 vaccine chatbot, cost analysis of governance system in health sector, situational analysis of infectious disease modelling in

Abstract Surrogate endpoints are frequently used as primary outcomes in clinical trials. This is appropriate when they are validated for their ability to predict clinical benefit measured on patient-relevant target outcome(s). Such validation is often lacking, thus increasing uncertainty in the dec

Gao Qi is a research assistant at Saw Swee Hock School of Public Health, National University of Singapore in collaboration with MIDAS. Research fields include framework construction of health innovation process, early health technology assessment, and traditional health technology assessment. Interested in health policy effects and health innovatio